Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.59 |
| ▸ | GCK | P35557 | 1/20 | 0.55 |
| ▸ | STK39 | Q9UEW8 | 3/20 | 0.53 |
| ▸ | RAF1 | P04049 | 2/20 | 0.49 |
| ▸ | ARAF | P10398 | 2/20 | 0.49 |
| ▸ | PNLIP | P16233 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | FADS1 | O60427 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17350355 | 0.91 | BRAF (0.64) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL11645838 | 0.87 | BRAF (0.70) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL17530350 | 0.83 | SIRT6 (0.56) | STK39PNLIPMAPK1GFER | |
| SCHEMBL17530346 | 0.78 | CYP2C9 (0.57) | STK39 | |
| SCHEMBL23096725 | 0.77 | FADS1 (0.51) | GCKMAPK1FADS1 | |
| SCHEMBL30777867 | 0.77 | ATF1 (0.47) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL30777864 | 0.77 | ATF1 (0.47) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL17530353 | 0.77 | ATF1 (0.47) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL28250577 | 0.76 | HDAC3 (0.55) | BRAFHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL11644538 | 0.76 | PNLIP (0.58) | BRAFHDAC1HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792251-B1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | ELANCO TIERGESUNDHEIT AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| EP-3186227-B1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | ELANCO TIERGESUNDHEIT AG (CH) | 2021-03-24 | — | — | EP | disclosed |
| EP-3792251-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | Elanco Tiergesundheit AG (CH) | 2021-03-17 | — | — | EP | disclosed |
| CN-106660961-B | Sulfonylaminobenzamide compounds as anthelmintics | 瑞士伊兰科动物保健有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10464889-B2 | Sulfonylaminobenzamide compounds as anthelmintics | ELANCO TIERGESUNDHEIT AG (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180319741-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | ELANCO TIERGESUNDHEIT AG (US) | 2018-11-08 | — | — | US | disclosed |
| US-20170226053-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | NOVARTIS TIERGESUNDHEIT AG (CH) | 2017-08-10 | — | — | US | disclosed |
| EP-3186227-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | Novartis Tiergesundheit AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033341-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | NOVARTIS TIERGESUNDHEIT AG (CH) | 2016-03-03 | — | — | WO | disclosed |
| EP-2990403-A1 | ANTHRANILAMIDES, SULFONAMIDES AND NITRO ANALOGUES DERIVED THEREFROM AS ANTHELMINTICS | Novartis Tiergesundheit AG (CH) | 2016-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226053-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | PKD2, CATSPER1, PKD1 | BRAF 2853/4885HDAC1 334/4885HDAC3 278/4885 |
| US-10464889-B2 | Sulfonylaminobenzamide compounds as anthelmintics | PKD2, CATSPER1, ATP1B2 | BRAF 2130/4885HDAC1 261/4885HDAC3 278/4885 |
| US-20180319741-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | PKD2, CATSPER1, PKD1 | BRAF 2853/4885HDAC1 334/4885HDAC3 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.